Monoclonal Antibodies in Hospitalised Patients with COVID-19: The Role of SARS-COV-2 Serostatus in an Evolving Pandemic
Abstract Appropriately selected neutralising monoclonal antibodies (nmAbs) are an effective treatment for patients with mild or moderate coronavirus disease 2019 (COVID-19) who are at high risk of progression to severe disease. In contrast, the efficacy of nmAbs in patients hospitalised with COVID-1...
Main Authors: | François Raffi, Robert L. Gottlieb |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2023-02-01
|
Series: | Infectious Diseases and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40121-023-00769-2 |
Similar Items
-
The impact of an unknown HIV serostatus on inpatient mortality
by: Yoshan Moodley
Published: (2017-11-01) -
Passive immunization with influenza haemagglutinin specific monoclonal antibodies
by: Rajeev Rudraraju, et al.
Published: (2018-11-01) -
Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
by: Lok Bahadur Shrestha, et al.
Published: (2021-09-01) -
Patient years lost due to cytomegalovirus serostatus mismatching in the scientific registry of transplant recipients
by: Maheen Z. Abidi, et al.
Published: (2024-01-01) -
HIV Serostatus Disclosure and Its Predictors Among Children Living With HIV in Ethiopia: A Systematic Review and Meta-Analysis
by: Tesfanesh Lemma, et al.
Published: (2022-06-01)